Drug Database
IN

insulin Aspart (NovoMix 30 Penfill / NovoMix 30 FlexPen / NovoRapid 30 Mix)

✓ Approved

Novo Nordisk A/S · INSR · Recombinant Proteins

What is insulin Aspart?

insulin Aspart is a recombinant proteins developed by Novo Nordisk A/S. It is approved for therapeutic indications via injectable (others) or subcutaneous injection.

Drug Profile

Brand NamesNovoMix 30 Penfill, NovoMix 30 FlexPen, NovoRapid 30 Mix
CompanyNovo Nordisk A/S
Drug ClassRecombinant Proteins
Molecular TargetINSR
RouteInjectable (Others), Subcutaneous Injection
StatusApproved
Sources: ClinicalTrials.gov, Novo Nordisk A/S

Mechanism of Action

Molecular Targets

insulin Aspart acts on 1 molecular target:

INSRinsulin receptor (CD220, HHF5)
Want deeper analysis?Noah AI can explain complex mechanisms and compare to similar drugs.

Therapeutic Indications

insulin Aspart is developed for 2 unique indications across 1 therapeutic area.

Therapeutic AreaConditionPhase
Metabolism and nutrition disordersType 2 diabetes mellitus✓ Approved
Metabolism and nutrition disordersType 1 diabetes mellitusPhase I

Related Research Articles

PubMedDiabetes research and clinical practice2026-08-30

Glycemic and safety outcomes of the insulin-only bionic pancreas in older adults and individuals with impaired awareness of Hypoglycemia: a post hoc analysis of a randomized pivotal trial.

Oktavian Puguh P, Kencono Wungu Citrawati Dyah CD, Amin Indah Mohd IM, Mudjanarko Sony Wibisono SW

Evaluate the efficacy and safety of iLet Bionic Pancreas (BP) in older adults and individuals with impaired awareness of hypoglycemia (IAH). This post hoc analysis used individual participant-level data from the Insulin-Only Bionic Pancreas Pivotal Trial (n = 440; NCT04200313). Eligible participants (n = 96) with type 1 diabetes, aged ≥ 60 years and/or had IAH (Clarke score ≥ 4), were randomized to BP with aspart/lispro (BP-Asp/Lis; n = 45), BP with fast-acting aspart configuration (BP-Fiasp; n = 31), or standard care (SC; n = 20) for 13 weeks. Compared with SC, time-in-range (70-180 mg/dL) significantly increased by 7.49 % (95 % CI: 2.61 to 12.38; ∼1.8 h/day) with BP-Asp/Lis and by 8.28 % (95 % CI: 3.15 to 13.41; ∼2.0 h/day) with BP-Fiasp, driven by reduced hyperglycemia. No significant differences were observed in hypoglycemia exposure. Severe hypoglycemia occurred in four participants (four events) on BP-Asp/Lis and one participant (two events) on SC. One diabetic ketoacidosis event occurred on BP-Fiasp due to an infusion set failure. In high-risk, clinically vulnerable populations, the BP system significantly improved glycemic control while maintaining safety parity with respect to hypoglycemia risk, providing a resilient therapeutic alternative for vulnerable cohorts.

PMID 42669381
Read full article →
PubMedSkeletal radiology2026-08-30

De novo osteosarcoma following prolonged denosumab treatment for giant cell tumor of bone at an anatomically distant site: a case report.

Burbank Katherine Elon KE, Henshaw Robert Mikael RM, Jelinek James Stephen JS, Murphey Mark D MD

Denosumab is a monoclonal antibody targeting RANKL, FDA-approved for the treatment of giant cell tumor of bone (GCTB). While it has shown efficacy in tumor regression and bone preservation, rare cases of malignant transformation to osteosarcoma have been associated with denosumab treatments. Previous literature has attributed such cases to either initial misdiagnosis of a malignant giant cell tumor at baseline presentation or, more rarely, transformation of previously histologically benign GCTB to a secondary malignant GCTB. To our knowledge, these cases involved or arose from an existing giant cell tumor neoplasm. We present a unique case of a patient who developed de novo osteosarcoma at a distant location from their original GCTB tumor following prolonged denosumab therapy, highlighting the clinical course, diagnostic challenges, and therapeutic considerations.

PMID 42668307
Read full article →
PubMedChemical communications (Cambridge, England)2026-08-30

Mapping conformational heterogeneity: 19F-Gd3+ ENDOR reveals otherwise hidden rotamer conformations.

Habel Edan E, Judd Martyna M, Huber Thomas T, Cox Nicholas N

19F-Gd3+ ENDOR is used to map the full conformational distribution of Trp42 in dihedral space in a de novo luminescent lanthanide-binding protein. By combining genetically encoded fluorination with regularisation modelling, we extract 19F-Gd3+ distance distributions, revealing a minor rotamer population proximal to the lanthanide, key for photoactivity.

PMID 42669308
Read full article →
PubMedThe Journal of veterinary medical science2026-08-30

Intraocular carcinosarcoma with osteosarcomatous component arising from iridociliary adenocarcinoma in a dog.

Kakimoto Miyuu M, Fukuyo Kotoko K, Miura Chisa C, Sano Yuto Y

A 9-year-old neutered male Labrador Retriever presented with increased intraocular pressure in the left eye and underwent enucleation for a suspected intraocular tumor. Grossly, a white to greyish-white solid mass occupied the anterior segment and was partially contiguous with the lens. Histologically, the tumor exhibited biphasic proliferation of epithelial and mesenchymal components. The mesenchymal component showed osteoid formation, and transitional features were observed between the two components. Based on histological and immunohistochemical findings, the tumor was diagnosed as a carcinosarcoma composed of an iridociliary adenocarcinoma component and an osteosarcomatous component. This is the first report of carcinosarcoma in the canine eye, expanding the understanding of the morphological diversity and histogenetic characteristics of canine iridociliary tumors.

PMID 42669475
Read full article →
PubMedBioinformatics and biology insights2026-08-30

De Novo Molecular Design and Bioactivity Prediction of Novel Hexahydroquinolines as Plasmodium falciparum Calcium-Dependent Protein Kinase 4 (CDPK4) Inhibitors.

Oduselu Gbolahan O GO, Bodun Damilola S DS, Ajani Olayinka O OO, Conway David J DJ et al.

Plasmodium falciparum Calcium-Dependent Protein Kinase 4 (PfCDPK4) is a validated target for malaria transmission-blocking interventions, as its inhibition disrupts male gametocyte exflagellation. Hexahydroquinolines (HHQs) have emerged as promising gametocytocidal agents. This study aimed to design novel HHQs as potential PfCDPK4 inhibitors with good binding affinity, favourable pharmacokinetics, and structural stability. A library of 20,000 novel HHQ analogs was generated using genetic algorithm-driven de novo molecular design in AlvaBuilder and systematically filtered through a pipeline comprising machine-learning-based bioactivity prediction, PAINS removal, pharmacophore modeling, ADMET screening, and structure-based virtual screening. Top-ranking compounds underwent bioisosteric optimization and were evaluated using 300 ns molecular dynamics simulations and density functional theory (DFT) calculations. Comparative in silico validation against known inhibitor Bumped Kinase Inhibitor-1 (BKI-1) and the co-crystallized ligand DXR as controls demonstrated that four HHQ analogs exhibited comparable binding affinities and stable interactions with key residues within the ATP-binding pocket. Favourable ADMET profiles, dynamic stability, and supportive electronic properties further reinforced their inhibition potential. These findings provide biologically meaningful computational evidence supporting HHQ scaffolds as potential PfCDPK4 inhibitors and demonstrate the utility of integrated bioinformatics approaches for malaria transmission-blocking drug discovery. Further experimental validation is required to confirm the inhibitory activities of the identified hexahydroquinoline compounds.

PMID 42668839
Read full article →
PubMediScience2026-08-30

Bacterial stress rewires diatom chronobiology and ecosystem function.

Chen Jiwei J, Diao Hang H, Su Yixi Y, Yuan Yuan Y et al.

Diatoms are vital primary producers in marine ecosystems and play a key role in blue carbon sequestration. Although their circadian rhythms have been studied in isolation, how these rhythms are modulated by co-occurring bacteria remains unknown. Using a defined co-culture of the diatom Phaeodactylum tricornutum with the marine bacterium Aliivibrio fischeri, we observed time-dependent physiological and transcriptomic changes in P. tricornutum, including a 16.3% reduction in rhythmic genes with prolonged culture time. Genome-scale metabolic modeling suggested a biphasic response, with predicted biomass flux increasing by 81% at the early co-culture stage but decreasing by 87% during prolonged co-culture. Deconvolution of the transcriptome via AI-driven independent component analysis identified gene modules associated with silica transport and senescence-related responses under co-culture conditions. Together, these findings establish a systems-level framework that links interspecies interactions between diatoms and bacteria, providing mechanistic insights into how microbial associations influence phytoplankton chronobiology and rhythmic regulation.

PMID 42668638
Read full article →

+9996 more articles available with a free account

Sign up free to view all articles →

Ask about insulin Aspart